Ascletis Selects Oral Amylin Receptor Peptide Agonist, ASC36, for Clinical Development

2026-02-10 - 23:38

– Utilizing Ascletis’ Peptide Oral Transport ENhancement Technology (POTENT), ASC36 oral tablets achieved absolute oral bioavailability of 6% to 8% at steady state, in non-human primate (NHP) studies. – In NHPs, ASC36 oral tablets reduced mean body weight up to 13.2% from baseline after once–daily dosing for 7 days. ASC36 tablets also reduced food intake